pS2 (TFF1) levels in human breast cancer tumor samples: Correlation with clinical and histological prognostic markers

Breast Cancer Research and Treatment

Volumn 56, Issue 3, 1999, Pages 253-265

  Gillesby, Bradley E ^a   Zacharewski, Timothy R ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Michigan State University   (United States)

Author keywords

Breast cancer; mRNA; Prognostic marker; pS2; RT PCR; TFF1

Indexed keywords

MESSENGER RNA; PROTEIN PS2;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER GRADING; CLINICAL FEATURE; CLINICAL TRIAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; TUMOR VOLUME;

EID: 0032698001     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1006215310169     Document Type: Article

References (58)

1. McGuire WL: Current status of estrogen receptors in human breast cancer. Cancer 36: 638-644, 1975
2. Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA, Osborne CK: Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26: 237-246, 1993
3. Benner SE, Clark GM, McGuire WL: Steroid receptors, cellular kinetics, and lymph node status as prognostic factors breast in cancer. Am J Med Sci 296: 59-66, 1988
4. Clark GM, McGuire WL: Progesterone receptors and human breast cancer. Breast Cancer Res Treat 3: 157-163, 1983
5. Foekens JA, Rio MC, Seguin P, van Putten WL, Fauque J, Nap M, Klijn JG, Chambon P: Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50: 3832-3837, 1990
6. Foekens JA, van Putten WL, Portengen H, Rodenburg CJ, Reubi JC, Berns PM, Henzen-Logmans SC, van der Burg ME, Alexieva-Figusch J, Klijn JG: Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer. J Steroid Biochem Mol Biol 37: 815-821, 1990
7. McGuire WL: Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5: 428-433, 1978
8. Osborne CK, Yochmowitz MG, Knight WAd, McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884-2888, 1980
9. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326: 1756-1761, 1992
10. Klijn JG, Berns EM, Foekens JA: Prognostic factors and response to therapy in breast cancer. Cancer Surv 18: 165-198, 1993
11. Cardiff RD: Cathepsin D and breast cancer: useful? Human Pathol 25: 847-848, 1994
12. Pichon MF, Milgrom E: Clinical significance of the estrogen regulated pS2 protein in mammary tumors. Crit Rev Oncol Hematol 15: 13-21, 1993
13. Rio MC, Chambon P: The pS2 gene, mRNA, and protein: a potential marker for human breast cancer. Cancer Cells 2: 269-274, 1990
14. Predine J, Spyratos F, Prud'homme JF, Andrieu C, Hacene K, Brunet M, Pallud C, Milgrom E: Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Correlation with prognosis and adjuvant hormome therapy. Cancer 69: 2116-2123, 1992
15. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P: Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 10: 7895-7903, 1982
16. May FF, Westley BR: Cloning of estrogen-regulated messenger RNA sequences from human breast cancer cells. Cancer Res 46: 6034-6040, 1986
17. Rio MC, Bellocq JP, Gairard B, Rasmussen UB, Krust A, Koehl C, Calderoli H, Schiff V, Renaud R, Chambon P: Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci USA 84: 9243-9247, 1987
18. Rio MC, Bellocq JP, Daniel JY, Tomasetto C, Lathe R, Chenard MP, Batzenschlager A, Chambon P: Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science 241: 705-708, 1988
19. Vateron PF, Chirino R, Vega V, Falcon O, Rivero JF, Torres S, Leon L, Fernandez L, Pestano J, Diaz-Chico B, Diaz-Chico JC: Quantitative analysis of p185(HER-2/neu) protein in breast cancer and its association with other prognostic factors. Int J Cancer 74: 175-179, 1997
20. Cappelletti V, Coradini D, Scanziani E, Benini E, Silvestrini R, Di Fronzo G: Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer. Eur J Cancer 28A: 1315-1318, 1992
21. Luqmani YA, Campbell T, Soomro S, Shousha S, Rio MC, Coombes RC: Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. Br J Cancer 67: 749-753, 1993
22. Pallud C, Le Doussal V, Pichon MF, Prud'homme JF, Hacene K, Milgrom E: Immunohistochemistry of pS2 in normal human breast and in various histological forms of breast tumuors. Histopathology 23: 249-256, 1993
23. Schwartz LH, Koerner FC, Edgerton SM, Sawicka JM, Rio MC, Bellocq JP, Chambon P, Thor AD: pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res 51: 624-628, 1991
24. Thor AD, Koerner FC, Edgerton SM, Wood WC, Stracher MA, Schwartz LH: pS2 expression in primary breast carcinomas: relationship to clinical and histological features and survival. Breast Cancer Res Treat 21: 111-119, 1992
25. Henry JA, Bennett MK, Piggott NH, Levett DL, May FE, Westley BR: Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Br J Cancer 64: 677-682, 1991
26. Ioakim-Liossi A, Karakitsos P, Aroni K, Markopoulos C, Delivelioti K, Gogas J, Kyrkou K: DNA ploidy and pS2 protein expression in breast cancer. Cytopathology 8: 171-176, 1997
27. Ioakim-Liossi A, Karakitsos P, Markopoulos C, Aroni K, Delivelioti K, Gogas J, Kyrkou K: Expression of pS2 protein and estrogen and progesterone receptor status in breast cancer. Acta Cytol 41: 713-716, 1997
28. Piggott NH, Henry JA, May FE, Westley BR: Antipeptide antibodies against the pNR-2 oestrogen-regulated protein of human breast cancer cells and detection of pNR-2 expression in normal tissues by immunohistochemistry. J Pathol 163: 95-104, 1991
29. Poulsom R, Hanby AM, Lalani EN, Hauser F, Hoffmann W, Stamp GW: Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J Pathol 183: 30-38, 1997
30. Soubeyran I, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM: Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 34: 119-128, 1995
31. Hurlimann J, Gebhard S, Gomez F: Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology 23: 239-248, 1993
32. Soubeyran I, Quenel N, Mauriac L, Durand M, Bonichon F, Coindre JM: Variation of hormonal receptor, pS2, c-erbB-2 and GST pi contents in breast carcinomas under tamoxifen - a study of 74 cases. Br J Cancer 73: 735-743, 1996
33. Inaji H, Koyama H, Motomura K, Noguchi S, Tsuji N, Wada A: Immunohistochemical survey of pS2 expression in intraductal lesions associated with invasive ductal carcinoma of the breast. Int J Cancer 55: 883-886 1993
34. Robbins PD, Hahnel E, Sterrett GF, Harvey J, Carrello S, Hahnel R: Expression of the pS2 gene in breast cancer - a comparison of pS2 protein radioimmunoassay and immunohistochemistry. Pathology 25: 255-260, 1993
35. Takahashi S, Narimatsu E, Asanuma H, Okazaki M. Okazaki A, Hirata K, Mori M, Chiba T, Sato N, Kikuchi K: Immunohistochemical detection of estrogen receptor in invasive human breast cancer: correlation with heat shock proteins, pS2 and oncogene products. Oncology 52: 371-375, 1995
36. Horiguchi J, Iino Y, Takei H: Expression of pS2 estrogen-inducible protein in primary breast cancer. Oncology 53: 12-15, 1996
37. Goussard J, Lechevrel C, Roussel G, Cren H., Bera O, Sala M: Immunoradiometric assay of pS2 protein in breast cancer cytosols. Clin Chem 37: 1759-1762, 1991
38. Henry JA, Nicholson S, Hennessy C, Lennard TW, May FE, Westley BR: Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy. Br J Cancer 61: 32-38, 1989
39. Skilton RA, Luqmani YA, McClelland RA, Coombes RC: Characterisation of a messenger RNA selectively expressed in human breast cancer. Br J Cancer 60: 168-175, 1989
40. McClelland RA, Manning DL, Gee JM, Anderson E, Clarke R. Howell A, Dowsett M, Robertson JF, Blamey RW, Wakeling AE, Nicholson RI: Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. Breast Cancer Res Treat 41: 31-41, 1996
41. Wysocki SJ, Iacopetta BJ, Ingram DM: Prognostic significance of pS2 mRNA in breast cancer. Eur J Cancer 30A: 1882-1884, 1994
42. Delvenne CG, Winkler-Gol RA, Piccart MJ, Hustin J, Michaux D, Leclercq G, Nogaret JM, Autier P: Expression of c-erbB2, TGF-beta 1 and pS2 genes in primary human breast cancers. Eur J Cancer 28: 700-705, 1992
43. Wundrack I, Mullenbach R, Welter C, Seitz G, Blin N: PCR expression analysis of the estrogen-inducible gene BCE1 in gastrointestinal and other human tumors. Dis Markers 12: 63-69, 1994
44. Dante R, Ribicras S. Baldassini S, Martin V. Benzerara O, Bouteille C, Bremond A, Frappart L, Rio MC, Lasne Y: Expression of an estrogen-induced breast cancer-associated protein (pS2) in benign and malignant human ovarian cysts. Lab Invest 71: 188-192, 1994
45. Carr M, May FE, Lennard TW, Westley BR: Determination of oestrogen responsiveness of breast cancer by competitive reverse transcription-polymerase chain reaction. Br J Cancer 72: 1427-1434, 1995
46. Ibrahim NB, Padfield CJ, Rees EJ, Wilson Y, Cawthorn SJ: Immunocytochemistry in the assessment of pS2 protein expression in fine needle aspiration cytology from breast carcinoma. Cytopathology 4: 323-330, 1993
47. Zimmermann K, Mannhalter JW: Technical aspects of quantitative competitive PCR. Biotechniques 21: 268-272, 274-279, 1996
48. Leygue E, Murphy L, Kuttenn F, Watson P: Triple primer polymerase chain reaction. A new way to quantify truncated mRNA expression. Am J Pathol 148: 1097-1103, 1996
49. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987
50. Sambrook J, Fritsch EF, Maniatis T: Molecular cloning: a laboratory manual. 2nd Edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989
51. Tsai SJ, Wiltbank MC: Quantification of mRNA using competitive RT-PCR with standard-curve methodology. Biotechniques 21: 862-866, 1996
52. Zachar V, Thomas RA, Goustin AS: Absolute quantification of target DNA: a simple competitive PCR for efficient analysis of multiple samples. Nucleic Acids Res 21: 2017-2018, 1993
53. Brown AM, Jeltsch JM, Roberts M, Chambon P: Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc Nad Acad Sci USA 81: 6344-6348, 1984
54. Hahnel E, Robbins P, Harvey J, Sterrelt G, Hahnel R: Expression of the pS2 gene in breast tissues assessed by pS2-mRNA analysis and pS2-protein radioimmunoassay. Breast Cancer Res Treat 24: 71-74, 1992
55. Horwitz KB, McGuire WL: Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 189: 726-727, 1975
56. Henry JA, Piggott NH, Mallick UK, Nicholson S, Farndon JR, Westley BR, May FE: pNR-2/pS2 immunohistochemical staining in breast cancer: correlation vdth prognostic factors and endocrine response. Br J Cancer 63: 615-622, 1991
57. Soubeyran I, Quenel N, Coindre JM, Bonichon F, Durand M, Wafflart J, Mauriac L: pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Br J Cancer 74: 1120-1125, 1996
58. Klijn JG, Berns PM, Bontenbal M, Alexieva Figusch J, Foekens JA: Clinical breast cancer, new developments in selection and endocrine treatment of patients. J Steroid Biochem Mol Biol 43: 211-221, 1992